Please Wait.....
Report
Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market
Market Report I 2023-10-01 I 188 Pages I Data Bridge Market Research
The Europe acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 2,764,971.40 thousand by 2030, from USD 1,356,879.02 thousand in 2022, growing at the CAGR of 9.7% in the forecast period of 2023 to 2030.
Market Segmentation
Europe Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, and rest of Europe) - Industry Trends and Forecast to 2030.
Overview of Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
- Increasing prevalence and incidence of acute lung injury in the market
Restraint
- High cost of device and treatment
Opportunity
- Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the Europe Acute Respiratory Distress Syndrome (ARDS) market are listed below:
- Gilead Sciences, Inc.
- Terumo Medical Corporation
- Getinge AB.
- LivaNova PLC
- Medtronic
- ResMed
- Fisher & Paykel Healthcare Limited.
- Dragerwerk AG & Co. KGaA
- NIPRO
- Fresenius SE & Co. KGaA
- Hamilton Medical
- Pfizer Inc.
- WEINMANN Emergency Medical Technology GmbH + Co. KG
- EUROSETS
- Armstrong Medical
- nice Neotech Medical Systems Pvt. Ltd.
- Besmed Health Business Corp.
TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PESTEL ANALYSIS 42
4.2 PORTER'S FIVE FORCES 43
4.3 INSURANCE REIMBURSEMENT 44
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44
4.3.3 ABBOTT CODING GUIDE FOR ECMO 45
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45
4.3.5 CERN HEALTH INSURANCE SCHEME 46
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46
4.3.7 AMERICAN HOSPITAL ASSOCIATION 47
4.4 PIPELINE ANALYSIS 48
4.5 PRICING ANALYSIS 50
5 MARKET OVERVIEW 51
5.1 DRIVERS 53
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54
5.2 RESTRAINTS 55
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55
5.2.2 HIGH COST OF DEVICES AND TREATMENT 55
5.3 OPPORTUNITIES 56
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57
5.4 CHALLENGES 58
5.4.1 STRINGENT RULES & REGULATIONS 58
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59
6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60
6.1 OVERVIEW 61
6.2 MECHANICAL VENTILATION 64
6.2.1 HIGH-FLOW NASAL O2 65
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65
6.2.4 PRONE POSITION VENTILATION 65
6.2.5 OTHERS 66
6.3 CORTICOSTEROIDS 66
6.3.1 METHYLPREDNISOLONE 67
6.3.2 DEXAMETHASONE 67
6.3.3 OTHERS 67
6.4 ANTIVIRAL MEDICATION 68
6.4.1 RIBAVIRIN 69
6.4.2 OSELTAMIVIR 69
6.4.3 OTHERS 69
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69
6.6 TOCILIZUMAB 70
6.7 OTHERS 70
?
7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71
7.1 OVERVIEW 72
7.2 SEPSIS 75
7.3 INHALATION OF HARMFUL SUBSTANCES 75
7.4 SEVERE PNEUMONIA 76
7.5 OTHERS 76
8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77
8.1 OVERVIEW 78
8.2 PARENTERAL 81
8.2.1 INTRAVENOUS 81
8.2.2 INTRAMUSCULAR 81
8.3 ORAL 82
8.4 OTHERS 82
9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83
9.1 OVERVIEW 84
9.2 HOSPITALS 87
9.3 SPECIALTY CLINICS 87
9.4 HOME HEALTHCARE 88
9.5 OTHERS 88
10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89
10.1 OVERVIEW 90
10.2 DIRECT TENDER 93
10.3 HOSPITAL PHARMACY 93
10.4 RETAIL PHARMACY 94
10.5 ONLINE PHARMACY 94
?
11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95
11.1 EUROPE 97
11.1.1 GERMANY 102
11.1.2 FRANCE 107
11.1.3 U.K. 112
11.1.4 ITALY 117
11.1.5 SPAIN 122
11.1.6 TURKEY 127
11.1.7 NETHERLANDS 132
11.1.8 SWITZERLAND 137
11.1.9 BELGIUM 142
11.1.10 RUSSIA 147
11.1.11 REST OF EUROPE 152
12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 153
12.1 COMPANY SHARE ANALYSIS: EUROPE 153
13 SWOT ANALYSIS 154
14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 155
14.1 GILEAD SCIENCES INC. 155
14.1.1 COMPANY SNAPSHOT 155
14.1.2 REVENUE ANALYSIS 156
14.1.3 COMPANY SHARE ANALYSIS 156
14.1.4 PRODUCT PORTFOLIO 157
14.1.5 RECENT DEVELOPMENT 157
14.2 TERUMO CORPORATION 158
14.2.1 COMPANY SNAPSHOT 158
14.2.2 REVENUE ANALYSIS 158
14.2.3 COMPANY SHARE ANALYSIS 159
14.2.4 PRODUCT PORTFOLIO 159
14.2.5 RECENT DEVELOPMENT 159
14.3 GETINGE 160
14.3.1 COMPANY SNAPSHOT 160
14.3.2 REVENUE ANALYSIS 160
14.3.3 COMPANY SHARE ANALYSIS 161
14.3.4 PRODUCT PORTFOLIO 161
14.3.5 RECENT DEVELOPMENT 161
14.4 LIVANOVA PLC 162
14.4.1 COMPANY SNAPSHOT 162
14.4.2 REVENUE ANALYSIS 162
14.4.3 COMPANY SHARE ANALYSIS 163
14.4.4 PRODUCT PORTFOLIO 163
14.4.5 RECENT DEVELOPMENTS 163
14.5 MEDTRONIC 164
14.5.1 COMPANY SNAPSHOT 164
14.5.2 REVENUE ANALYSIS 164
14.5.3 COMPANY SHARE ANALYSIS 165
14.5.4 PRODUCT PORTFOLIO 165
14.5.5 RECENT DEVELOPMENTS 165
14.6 ARMSTRONG MEDICAL 166
14.6.1 COMPANY SNAPSHOT 166
14.6.2 PRODUCT PORTFOLIO 166
14.6.3 RECENT DEVELOPMENT 166
14.7 BESMED HEALTH BUSINESS CORP. 167
14.7.1 COMPANY SNAPSHOT 167
14.7.2 PRODUCT PORTFOLIO 167
14.7.3 RECENT DEVELOPMENTS 168
14.8 DRAGERWERK AG & CO. KGAA 169
14.8.1 COMPANY SNAPSHOT 169
14.8.2 REVENUE ANALYSIS 169
14.8.3 PRODUCT PORTFOLIO 170
14.8.4 RECENT DEVELOPMENTS 170
14.9 EUROSETS 171
14.9.1 COMPANY SNAPSHOT 171
14.9.2 PRODUCT PORTFOLIO 171
14.9.3 RECENT DEVELOPMENT 171
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 172
14.10.1 COMPANY SNAPSHOT 172
14.10.2 REVENUE ANALYSIS 172
14.10.3 PRODUCT PORTFOLIO 173
14.10.4 RECENT DEVELOPMENTS 173
14.11 FRESENIUS SE & CO. KGAA. 174
14.11.1 COMPANY SNAPSHOT 174
14.11.2 REVENUE ANALYSIS 174
14.11.3 PRODUCT PORTFOLIO 175
14.11.4 RECENT DEVELOPMENT 175
?
14.12 HAMILTON MEDICAL 176
14.12.1 COMPANY SNAPSHOT 176
14.12.2 PRODUCT PORTFOLIO 176
14.12.3 RECENT DEVELOPMENT 176
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 177
14.13.1 COMPANY SNAPSHOT 177
14.13.2 PRODUCT PORTFOLIO 177
14.13.3 RECENT DEVELOPMENT 177
14.14 NIPRO 178
14.14.1 COMPANY SNAPSHOT 178
14.14.2 REVENUE ANALYSIS 178
14.14.3 PRODUCT PORTFOLIO 179
14.14.4 RECENT DEVELOPMENT 179
14.15 PFIZER INC. 180
14.15.1 COMPANY SNAPSHOT 180
14.15.2 REVENUE ANALYSIS 180
14.15.3 PRODUCT PORTFOLIO 181
14.15.4 RECENT DEVELOPMENT 181
14.16 RESMED 182
14.16.1 COMPANY SNAPSHOT 182
14.16.2 REVENUE ANALYSIS 182
14.16.3 PRODUCT PORTFOLIO 183
14.16.4 RECENT DEVELOPMENT 183
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 184
14.17.1 COMPANY SNAPSHOT 184
14.17.2 PRODUCT PORTFOLIO 184
14.17.3 RECENT DEVELOPMENT 184
15 QUESTIONNAIRE 185
16 RELATED REPORTS 188
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security